• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    北

    北挪威大学医院

    University Hospital of North Norway,Northern Norway Regional Health Authority
    3,688论文总数
    11.2万引用总数

    The University Hospital of North Norway (Norwegian: Universitetssykehuset Nord-Norge) or UNN is a hospital and health trust.UNN is a university hospital for the region which includes the counties of Nordland, Troms and Finnmark. It is part of the Northern Norway Regional Health Authority (Norwegian: Helse Nord). Its service area has a combined population of 465,000. Patient treatment and diagnostic investigation as well as training and research takes place at eleven clinics. The hospital system provides local hospital services to the 110,000 inhabitants of the Tromsø area, as well as the inhabitants of southern Troms and northern Nordland from facilities located in Harstad, Longyearbyen and Narvik.UNN also serves the regional Emergency Medical Communication Center (Akuttmedisinsk kommunikasjonssentral) and operates a number of ambulance stations in Nordland and Troms.

    论文量&引用量时间轴

    机构学者

    论文(3689)

    年份
    起
    –
    止
    排序
    1Safety and Efficacy of Daratumumab in Immune Thrombocytopenia.
    Galina Tsykunova,Pål Andre Holme,Hoa Thi Tuyet Tran,Henrik Frederiksen,Eirik Tjønnfjord,Ludvig A Munthe, Elsa Drivet,Hassen Kared, Ingvild Hausberg Sørvoll,Maria Therese Ahlen,Matthiéu Mahévas,Marc Michel,

    ABSTRACT:Resistance to B-cell-targeted therapies in immune thrombocytopenia (ITP) has been linked to persistence of autoantibody-producing CD38+ long-lived plasma cells. CD38 antibody daratumumab has been proposed as a potential therapy for ITP. This multicenter, open-label, phase 2 study evaluated safety and efficacy of daratumumab in 21 patients with previously treated ITP. Following a safety run-in, 2 dosing cohorts received 8 and 10 subcutaneous injections of 1800 mg daratumumab weekly, respectively. Primary end points were safety and response (2 consecutive platelet counts ≥50 × 109/L at week 12 for the safety run-in/cohort 1, and at week 16 for cohort 2). At baseline, median platelet count was 17 × 109/L, median number of prior therapies was 4. Most treatment-emergent adverse events were transient grade 1 to 2, most commonly infections (38%). Two patients (4.7%) experienced grade 3 adverse events, 1 infusion-related reaction, and 1 severe acute respiratory syndrome coronavirus 2 infection with acute renal failure. Ten patients (48%) met the primary efficacy end point. Sustained response (2 consecutive platelet counts ≥50 × 109/L at week 24) was achieved in 8 patients (38%), of whom 2 later relapsed. Response and relapse rates did not differ between cohorts. Patient-reported quality of life measured by 36-Item Short-Form Health Survey improved in responding patients. Daratumumab decreased immunoglobulin levels in all patients, and substantially reduced CD38+ cells in peripheral blood and bone marrow. There was no significant difference in antiplatelet antibodies between responders and nonresponders. This study confirms CD38 as an important target in ITP. This trial was registered at clinicaltrials.gov as #NCT04703621, and at the European Clinical Trial Register (EudraCT #2019-004683-22).

    2026Blood advances(2026)引用:8
    引用
    AI阅读
    加入学术空间
    2Ancestry-Associated Performance Variability of Open-Source AI Models for EGFR Prediction in Lung Cancer.
    Mehrdad Rakaee, Amin H Nassar, Masoud Tafavvoghi, Falah Jabar, Elias Bou Farhat, Elio Adib,Sigve Andersen, Lill-Tove Rasmussen Busund,Mette Pøhl,Åslaug Helland,Alexander Gusev,Biagio Ricciuti,

    Importance:Artificial intelligence (AI) models are emerging as rapid, low-cost tools for predicting targetable genomic alterations directly from routine pathology slides. Although these approaches could accelerate treatment decisions in lung cancer, little is known about whether their performance is consistent across diverse patient populations and tissue contexts. Objective:To evaluate the performance and generalizability of 2 open-source AI pathology models for predicting EGFR mutation status in lung adenocarcinoma (LUAD) across independent cohorts and ancestral subgroups. Design, Setting, and Participants:This cohort study included patients with LUAD from 2 cohorts: Dana-Farber Cancer Institute (DFCI) from June 2013 to November 2023, and a European-based trial (TNM-I) from August 2016 to February 2022. All patients had paired next-generation sequencing data and hematoxylin-eosin-stained whole-slide images. In the DFCI cohort, genetic ancestry was inferred using germline genotype data. Data analyses were performed from July 2025 to September 2025. Main Outcomes:The primary outcome was model performance for predicting EGFR mutation status, measured as the area under the receiver operating characteristic curve (AUC), evaluated overall and across ancestry subgroups and sample types. Results:Overall, 2098 patients with LUAD were included (mean [SD] age, 66.6 [10.3] years; 1315 female individuals [63%] and 783 male individuals [37%]). In the DFCI cohort (n = 1759; 54 African, 101 American, 95 Asian, 1465 European), EGFR mutations were detected in 432 patients (25%). One AI-pathology model achieved an AUC of 0.83 (95% CI, 0.81-0.85) compared with 0.68 (95% CI, 0.65-0.70) for the other model. In the TNM-I cohort (n = 339), EGFR mutations were detected in 50 patients (15%), with AUCs of 0.81 (95% CI, 0.74-0.88) and 0.75 (95% CI, 0.68-0.83), respectively. In ancestry-stratified analyses of the DFCI cohort, AUCs for the higher-performing model were 0.84 (95% CI, 0.81-0.86) in patients of European ancestry, 0.85 (95% CI, 0.72-0.94) in African ancestry, and 0.68 (95% CI, 0.55-0.78) in Asian ancestry. In sample type analyses, performance declined in pleural (AUC, 0.66; 95% CI, 0.56-0.76) compared with lung specimens (AUC, 0.86; 95% CI, 0.83-0.88). AI-guided triage analyses showed a potential 57% reduction in rapid EGFR testing, while maintaining sensitivity of 0.84 and specificity of 0.99. Conclusions:This cohort study found that AI-based pathology tools may serve as preliminary adjuncts for EGFR prediction in lung cancer, though performance differences by ancestry warrant careful interpretation.

    2026JAMA oncology(2026)引用:4
    引用
    AI阅读
    加入学术空间
    3Prognostic Value of N-terminal Pro-B-type Natriuretic Peptide and C Reactive Protein Testing in Patients with Acute ST-segment Elevation Myocardial Infarction.
    Ioana Mihaela Dregoesc,Dana Cramariuc,Tom Wilsgaard, Mihnea Istrate, Victor Stefan Buiga, Stanca Ichim, Camelia Ober, Simona Manole,Ekaterina Sharashova, Michael Stylidis,Judy Hung,Adrian Corneliu Iancu,

    BACKGROUND:Biomarkers could improve risk stratification in patients with acute ST-segment elevation myocardial infarction (STEMI), beyond left ventricular ejection fraction (LVEF). Our study evaluated the association between N-terminal pro-B-type natriuretic peptide (NT-proBNP), C reactive protein (CRP) and mortality in a cohort of patients with acute STEMI. METHODS:This prospective, observational cohort study included patients with reperfused acute STEMI admitted to a tertiary cardiovascular disease centre between July 2020 and October 2023. All patients underwent NT-proBNP and CRP testing. The association between NT-proBNP, CRP and all-cause mortality was evaluated in relation to predischarge LVEF. RESULTS:The cohort included 566 patients with a mean age of 63 years. After a median follow-up of 39 months, postdischarge all-cause mortality reached 13.4%. NT-proBNP was associated with mortality irrespective of LVEF (HR 2.34 per SD increment in log NT-proBNP; p<0.001 at LVEF <50% and HR 2.36; p=0.004 at LVEF ≥50%), but the association between CRP and mortality was significant only in patients with LVEF <50% (HR 1.55, p=0.003). Across the cohort, NT-proBNP remained associated with death after adjustment for age, sex, diabetes, baseline high-sensitivity cardiac troponin T (hs-cTnT), CRP, final Thrombolysis in myocardial infarction (TIMI) flow grade and reduced LVEF (HR 1.45, p=0.03). In patients with preserved LVEF, routine NT-proBNP testing (area under the curve (AUC) 0.753 (0.642-0.863), p<0.001) improved risk stratification compared with isolated LVEF assessment (AUC 0.592 (0.453-0.730), p=0.18). CONCLUSIONS:In a cohort of stabilised acute STEMI survivors, NT-proBNP was associated with all-cause mid-term mortality independent of hs-cTnT and LVEF. The association between CRP and mortality was significant only in patients with LVEF <50%.

    2026Open heart(2026)引用:2
    引用
    AI阅读
    加入学术空间
    4Rebuilding Gaza's Health System: A Qualitative Study of Healthcare Workers' Experiences and Lessons Learned from Responding to Mass Casualty Incidents (2018-2021).
    Anas Ismail, Moatasem Salah,Mads Gilbert, Yousef H Abu Alreesh,Craig Jones

    BackgroundGaza has faced numerous military attacks that resulted in mass casualty incidents (MCIs). The ongoing genocide in Gaza has destroyed much of the health system, including killing and injuring of hundreds of health care workers (HCWs). Current thinking on the health system reconstruction lacks empirical data and local HCWs' perspectives. The study analyses locally driven innovations and lessons learned by HCWs who responded to MCIs between 2018 and 2021 to guide current and future planning of the reconstruction of the health system in Gaza.MethodsThis was a qualitative study using online and face-to-face interviews with HCWs who responded to the Great March of Return and the 2021 Israeli military attacks. Transcripts and extensive notes from the interviews were recorded and analyzed on NVivo using thematic content analysis. We used the health system building blocks as themes for deductive analysis with a seventh place-based theme (Gaza-specific) to account for the context of Gaza and the MCIs.ResultsProblems faced by HCWs mostly related to the nature and complexity of traumatic injuries, shortages in HCWs, particularly specialist doctors, poor coordination among actors, duplication of services, and shortages of supplies and equipment. Locally driven innovations and solutions included establishing new services centers, opening and expanding training programs, starting new coordination bodies, and task shifting of staff and facilities. Lessons learned included strengthening training and employment opportunities for staff, enhancing emergency preparedness and capacities, maintaining coordination bodies, enhancing community engagement and strengthening the governance of the Ministry of Health.ConclusionReconstruction of Gaza's health system needs to be grounded in its political context and in the experiences of HCWs who have worked in and managed the system. Locally driven solutions and lessons learned can ensure that reconstruction serves as a vehicle for self-determination and sovereignty, rather than entrenching dependency.

    2026引用:2
    引用
    AI阅读
    加入学术空间
    5Cervical Cytology and HPV16/18/45 Mrna Co-Testing Improve Risk Stratification in Routine Clinical Practice.
    Sveinung Wergeland Sørbye, Bente Marie Falang, Mona Antonsen, Elin Richardsen

    Background/Objectives: Co-testing may improve cervical cancer prevention by stratifying women into groups with different absolute risks of CIN2+, CIN3+, and cervical cancer. We evaluated real-world co-testing with cervical cytology and a genotype-specific HPV E6/E7 mRNA assay targeting HPV16, HPV18, and HPV45 (PreTect SEE) in routine clinical practice. Methods: We conducted a retrospective, registry-based cohort study at the Department of Clinical Pathology, University Hospital of North Norway. Eligible co-test samples (liquid-based cytology with concurrent HPV mRNA testing, both with valid results) from routine screening, follow-up, and clinically indicated testing were identified from the laboratory information system and passively followed for worst histological outcome through December 2025. Outcomes were no biopsy/<CIN2, CIN2+, CIN3+, and cervical cancer. Results: Among 116,217 eligible co-test samples (mean age 43.9 years), cumulative risks were 4.4% for CIN2+, 1.5% for CIN3+, and 0.1% for cervical cancer. Baseline HPV mRNA positivity was 3.9%, and cytology was ASC-US+ in 12.2% of samples. Co-testing produced a clear stepwise risk gradient. Double-negative results (NILM/mRNA-; 86.7%) had very low risks (CIN3+ 0.2%; cervical cancer 0.02%). ASC-US+/mRNA- results (9.3%) showed intermediate risks (CIN3+ 4.1%; cervical cancer 0.2%). NILM/mRNA+ results (1.1%) showed substantially higher risks despite normal cytology (CIN3+ 13.0%; cervical cancer 0.5%). Double-positive results (ASC-US+/mRNA+; 2.8%) had the highest risks (CIN3+ 28.5%; cervical cancer 2.3%). Within NILM, mRNA positivity captured 42.7% of CIN3+ cases and 25.0% of cancers. Genotype-specific analyses showed highest risks for HPV16, followed by HPV18 and HPV45. Conclusions: Co-testing with cervical cytology and a 3-type HPV mRNA assay provided strong, clinically interpretable risk stratification and identified a small but high-risk subgroup among women with normal cytology. These findings support genotype-specific HPV mRNA testing as an adjunct to cytology in routine care.

    2026Cancers(2026)引用:2
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 3689 篇论文

    合作机构(100)

    特罗姆瑟大学合作论文 1,133
    挪威奥斯陆大学医院合作论文 683
    奥斯陆大学合作论文 369
    圣奥拉夫大学医院合作论文 209
    Haukeland 大学医院合作论文 202
    卑尔根大学合作论文 186
    阿克斯胡斯大学医院合作论文 179
    斯塔万格大学医院合作论文 171
    挪威科技大学合作论文 118
    卡罗琳斯卡医学院合作论文 110

    机构统计